Product Images Glucose

This document is a notification from Baxter Healthcare Corporation regarding the temporary importation of various intravenous products to address drug shortages. The products include 0.9% Sodium Chloride Injection, 5% and 10% Glucose Injection, and a combination of 5% Glucose/0.9% Sodium Chloride Injection from Baxter's manufacturing facility in Shanghai, China. This temporary measure is being coordinated with the U.S. Food and Drug Administration (FDA). The document provides details on specific product sizes, codes, and handling instructions to ensure product integrity and sterility. Additionally, healthcare professionals are advised to visually inspect the bags for particulate matter or leaks before administration, emphasizing the importance of product safety.*

The text provides detailed information about the differences between FDA-approved and imported medical products, specifically related to glucose and sodium chloride injections. It highlights issues such as incompatible barcodes, potential mislabeling, differences in energy content, and the need for adjustments in protocols and compounding systems when using the imported products. The text emphasizes the importance of manual inputting of product information and caution in handling the solution containers for the imported products. It also mentions specific products and their respective differences in composition and labeling. The tables included at the end of the text provide a visual reference for the discrepancies between the approved and imported products. The document seems to be a product evaluation or comparison report for healthcare professionals.*

This text provides information on how to report adverse events or product quality issues related to FDA-approved and imported 5% Dextrose/0.9% Sodium Chloride Injection solutions. It includes contact details for reporting to Baxter or FDA's MedWatch program. Additionally, it offers links to prescribing information for different product variants, such as 5% Glucose Injection or 10% Dextrose Injection. Instructions are given for reporting product quality issues and obtaining translated prescribing information. Contact details for Baxter's Medical Information Service and Center for Service are also provided for inquiries or placing orders.*

This is a comparison table listing key differences between an FDA-approved 0.9% Sodium Chloride Injection USP and an imported product from Shanghai, China. It includes information such as product names, label volumes, language of indications, active ingredients, additional information, storage conditions, container types, and medication administration details. The table provides a clear overview of the distinctions between the two products and their specifications.*

This is a table that includes label images of FDA-approved and imported 0.9% Sodium Chloride Injection USP products. It provides details on the difference between the FDA-approved product and the imported product from Shanghai, China. The imported product has a label in black color with a barcode, while the FDA-approved product also has a black label but does not show the barcode. The table mentions the NDC number, which is not shown below, for the imported product. The imported product's barcode location is indicated to have a linear barcode with human-readable information. The labels also mention the brand Baxter® AsC1324US and include details about Sodium Chloride Injection in 1000ml size.*

This is a comparison of FDA-approved 5% Dextrose Injection USP and imported 5% Glucose Injection. The FDA-approved product, known as 5% Dextrose Injection USP, is indicated as a source of water and calories. Each 100 ml contains 5 g Dextrose Hydrous USP. It has an osmolarity of 252 mOsmol/L and caloric content of 10 kcal. It is stored at room temperature 25°C/77°F in a virLex container with medication and administration port closures as described. On the other hand, the imported product from Shanghai, China, known as 5% Glucose Injection, is also indicated as a source of water and calories. Each 100 ml contains 5 g Anhydrous Glucose, with an osmolarity of 278 mOsmol/L and caloric content of 200 kcal/T. It needs to be stored at room temperature 15°C/59°F to 30°C/86°F in an INA container with different medication and administration port closures. The comparison of these products may help in making an informed choice based on individual needs and preferences.*

The text provides a comparison between FDA-approved 5% Dextrose Injection USP and an imported 5% Glucose Injection. It mentions the origin of the imported product from Shanghai, China. The labels of both products are described, including label color and representative label size. The Baxter brand is mentioned in the description as well. Additionally, details about barcode presence and NDC number inclusion for the imported product are highlighted.*

This text describes key differences between FDA-approved 10% Dextrose Injection USP and imported 10% Glucose Injection. The differences are outlined in terms of product name, label volume, language, indications, active ingredients, additional information such as osmolarity and caloric content, storage conditions, container type, and administration ports and protectors. The FDA-approved product contains Dextrose Hydrous, while the imported product contains Anhydrous Glucose. Storage instructions vary between the two products, and the container types and administration ports differ as well. Each product comes with its own administration protector in different colors.*

This is a comparison between FDA-approved 10% Dextrose Injection USP and imported 10% Glucose Injection from Shanghai, China. The FDA-approved product is labeled with black text and does not show a barcode, while the imported product has a black label and includes an NDC number but does not show the barcode. The imported product label mentions a linear barcode with human-readable information. The label for the imported product also displays the brand Baxter and indicates it is a Glucose Injection with 10% strength in a 50ml container.*

This text provides a comparison between FDA-approved 5% Dextrose/0.9% Sodium Chloride Injection USP and imported 5% Glucose/0.9% Sodium Chloride Injection, highlighting key differences in product details such as label volume, language, active ingredients, osmolarity, calorie content, and storage conditions. It also mentions the container type and administration port closures for each product variant.*

This text provides a comparison between FDA-approved 5% Dextrose/0.9% Sodium Chloride Injection USP and imported 5% Glucose/0.9% Sodium Chloride Injection products. It includes details such as the label colors, origin of the imported product from Shanghai, China, and the mention of NDC numbers on the imported product. The text seems to discuss the components and specifications of these two types of injections.*

This text is an extract from a glucose injection package insert. It includes information about the drug name, ingredients, indications, dosage, administration, and possible side effects. It emphasizes the importance of proper dosage calculation based on individual patient needs and conditions. The text also highlights the risks of incorrect administration, such as hyperosmolarity, electrolyte disturbances, dehydration, hypoglycemia, and other adverse reactions. Proper medical supervision and monitoring are recommended during glucose therapy to prevent complications.*

Description not available.*

This description contains details about a 10% Glucose Injection product in 250ml quantity. It includes information such as LOT numbers, expiration dates, manufacturing date, and other identification codes. The product is intended for medical use and is available in a package size containing 40 units. The text provides essential information for tracking and monitoring the product's quality and usage.*